{
  "data": {
    "baseMatches": {
      "totalCount": 41,
      "edges": [
        {
          "node": {
            "nctId": "NCT02942264",
            "title": "Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma",
            "conditions": "[\"Brain Tumor\", \"Astrocytoma\", \"Astroglioma\", \"Glioblastoma\", \"Gliosarcoma\"]",
            "gender": "All",
            "phase": "Phase 1/Phase 2",
            "minimumAge": 18,
            "maximumAge": 120,
            "sites": [
              {
                "facility": "National Institutes of Health Clinical Center",
                "contactName": "For more information at the NIH Clinical Center contact National Cancer Institute Referral Office",
                "contactEmail": "",
                "contactPhone": "888-624-1937",
                "latitude": 39.0023604,
                "longitude": -77.097455
              }
            ],
            "studyType": "Interventional",
            "meshTerms": [
              "GLIOBLASTOMA",
              "BRAIN_NEOPLASMS",
              "ASTROCYTOMA",
              "GLIOSARCOMA",
              "TEMOZOLOMIDE"
            ],
            "interventions": [
              {
                "description": "Phase I: Two treatment arms and several dose levels are planned; In the MTD finding part, TMZ with two alternate schedules (dd and mn) in combination with Zotiraciclib (TG02) will be administered;\n--A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: ( winner of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design. The dosage for the combination arm will be derived from the MTD determined in the Phase I component of the study.",
                "arm_group_labels": [
                  "Phase I Arm 1",
                  "Phase I Arm 2",
                  "Phase II Arm 1"
                ],
                "intervention_name": "Zotiraciclib (TG02)",
                "intervention_type": "Drug"
              },
              {
                "description": "Phase I: In the MTD finding part, TMZ with two alternate schedules (dd and mn) in combination with Zotiraciclib (TG02) will be administered; A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: (\"winner\" of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design.",
                "arm_group_labels": [
                  "Phase I Arm 1",
                  "Phase I Arm 2",
                  "Phase II Arm 1",
                  "Phase II Arm 2"
                ],
                "intervention_name": "TMZ",
                "intervention_type": "Drug"
              }
            ],
            "advancedMatchConditions": [
              {
                "conditions": "[\"Central Nervous System Tumors\", \"Brain Neoplasm\", \"Glioblastoma\", \"Gliosarcoma\", \"Ganglioglioma\", \"Meningioma\", \"Astrocytoma\", \"Oligodendroglioma\", \"Ependymoma\", \"Choroid plexus tumors\", \"Neuronal tumors\", \"Pineal tumors\", \"Neuroectodermal tumors\", \"Atypical teratoid rhabdoid tumor\", \"Schwannoma\", \"Central Nervous System Mesenchymal tumors\", \"Central Nervous System Lymphoma\", \"Central Nervous System Germ Cell tumors\", \"Craniopharyngioma\"]",
                "advancedMatchConditionReview": {
                  "formSchemaAnswers": null
                }
              }
            ]
          }
        }
      ]
    }
  }
}
